This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Voltaren Gel

Endo International plc

Drug Names(s): diclofenac sodium topical gel 1%

Description: BioMedTracker has separate drug profiles for the oral and topical formulations of Voltaren. Please also see Voltaren/XR.

Voltaren Gel provides 1% diclofenac sodium in a topical gel formulation. It is a non-steroidal anti-inflammatory (NSAID) medication with analgesic, anti-inflammatory, and antipyretic properties. The major mechanism of action of NSAIDS is believed to be inhibition of cycloxygenase activity and prostaglandin synthesis. The amount of diclofenac sodium that is systemically absorbed from Voltaren Gel is on average 6% of the systemic exposure from a comparable dose of an oral form of diclofenac sodium.

Deal Structure: Endo and Novartis
In March 2008, Endo Pharmaceuticals announced that it has entered into a licensing agreement with Novartis to obtain the exclusive U.S. marketing rights for Voltaren Gel. Under the terms of the five-year agreement with Novartis, Endo will make an upfront cash payment of $85 million. Novartis is also eligible to receive a one-time milestone payment of $25 million if annual sales exceed $300 million. Novartis will receive royalties on the net sales of Voltaren Gel in the U.S. and will supply this product to Endo.

Phosphagenics and Themis
In November 2011, Phosphagenics announced a licensing agreement with Themis Medicare of India to manufacture and sell a diclofenac gel in India incorporating Phosphagenics TPM drug delivery technology.

In May 2016, Phosphagenics announced that it has expanded its existing agreement with Themis Medicare Limited for its TPM/Diclofenac gel, to include an additional 16 geographical markets. The expanded...See full deal structure in Biomedtracker

Partners: Novartis AG Phosphagenics Limited Themis Medicare Ltd

Voltaren Gel News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug